SCM Lifescience Co. Ltd
SCM Lifescience Co., Ltd. operates as a stem cell therapy company in South Korea. It develops SCM-AGH, a treatment for moderate to severe acute pancreatitis and moderate to severe atopic dermatitis, as well as chronic graft versus host disease; and Iroro Deerscalp, a toothbrush cosmetic for hair loss relief. The company was founded in 2014 and is headquartered in Incheon, South Korea.
SCM Lifescience Co. Ltd (298060) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.057x
Based on the latest financial reports, SCM Lifescience Co. Ltd (298060) has a cash flow conversion efficiency ratio of -0.057x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.40 Billion) by net assets (₩24.38 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
SCM Lifescience Co. Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how SCM Lifescience Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
SCM Lifescience Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SCM Lifescience Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Innelec Multimedia
PA:ALINN
|
-0.574x |
|
Triangle Energy (Global) Ltd
AU:TEG
|
-2.119x |
|
Suvidhaa Infoserve Limited
NSE:SUVIDHAA
|
0.191x |
|
415380
KQ:415380
|
0.023x |
|
Famous Brands Ltd
JSE:FBR
|
0.246x |
|
Euromax Resources Ltd
PINK:EOXFF
|
0.059x |
|
LITHIA MTRS
BE:LMO
|
0.033x |
|
Saint Jean Carbon Inc
OTCQB:TORVF
|
-0.054x |
Annual Cash Flow Conversion Efficiency for SCM Lifescience Co. Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of SCM Lifescience Co. Ltd from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩14.18 Billion | ₩-10.05 Billion | -0.709x | -19.61% |
| 2023-12-31 | ₩20.47 Billion | ₩-12.14 Billion | -0.593x | -30.05% |
| 2022-12-31 | ₩24.51 Billion | ₩-11.17 Billion | -0.456x | -51.71% |
| 2021-12-31 | ₩44.61 Billion | ₩-13.40 Billion | -0.300x | -74.03% |
| 2020-12-31 | ₩63.08 Billion | ₩-10.89 Billion | -0.173x | +65.46% |
| 2019-12-31 | ₩16.85 Billion | ₩-8.42 Billion | -0.500x | -439.71% |
| 2018-12-31 | ₩-44.60 Billion | ₩-6.56 Billion | 0.147x | -74.42% |
| 2017-12-31 | ₩-8.67 Billion | ₩-4.99 Billion | 0.575x | -- |